Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

Simon Chowdhury, MA, MBBS, MRCP, PhD
Published: Wednesday, Jul 12, 2017



Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting. 


Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x